Department of Oncology, Instituto Alexander Fleming, Buenos Aires, Argentina.
Department of Medical Oncology, Hospital Nacional de Cancerología, Ciudad de México, México.
Future Oncol. 2021 May;17(13):1601-1609. doi: 10.2217/fon-2020-1152. Epub 2021 Jan 8.
FLABRA evaluated the prevalence of mutations, genetic counseling and management approaches in patients with ovarian cancer in Latin America. Patients with ovarian cancer from six Latin-American countries were enrolled. Tumor samples were tested for mutations (). In cases with , blood samples were analyzed to determine germline versus somatic mutations. Medical records were reviewed for counseling approach and treatment plan. From 472 patients enrolled, 406 samples yielded conclusive results: 282 were wild-type (), 115 were and nine were variants of uncertain significance. In total, 110/115 were tested for germline mutations (77 germline and 33 somatic). Tumor testing to identify mutations in in ovarian cancer can help optimize treatment choices, meaning fewer patients require germline testing and genetic counseling, a scant resource in Latin America. NCT02984423 (ClinicalTrials.gov).
FLABRA 评估了拉丁美洲卵巢癌患者中 突变、遗传咨询和管理方法的流行情况。来自六个拉丁美洲国家的卵巢癌患者入组。肿瘤样本进行了 突变检测（）。在存在 的情况下，分析血液样本以确定胚系与体细胞突变。查阅病历以了解咨询方法和治疗计划。在纳入的 472 名患者中，406 个样本得出了明确的结果：282 个为 野生型（），115 个为 ，9 个为意义不明的变异体。总共，对 115 个中的 110 个进行了胚系突变检测（77 个胚系和 33 个体细胞）。肿瘤检测以鉴定 卵巢癌中的突变可以帮助优化治疗选择，这意味着较少的患者需要进行胚系检测和遗传咨询，而拉丁美洲的这种资源稀缺。NCT02984423（ClinicalTrials.gov）。
